Open Access

miR-204 reverses temozolomide resistance and inhibits cancer initiating cells phenotypes by degrading FAP-α in glioblastoma

  • Authors:
    • Yun‑Na Yang
    • Xiang‑Hua Zhang
    • Yan‑Ming Wang
    • Xi Zhang
    • Zheng Gu
  • View Affiliations

  • Published online on: March 20, 2018     https://doi.org/10.3892/ol.2018.8301
  • Pages: 7563-7570
  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Malignant gliomas are treated with temozolomide (TMZ) at present, but often exhibit resistance to this agent. Cancer-initiating cells (CICs) have been suggested to lead to TMZ resistance. The mechanisms underlying CICs‑based TMZ resistance are not fully understood. MicroRNAs (miRNAs) have been demonstrated to serve important roles in tumorigenesis and TMZ resistance. In the present study, a sphere forming assay and western blot analysis were performed to detect the formation of CICs and fibroblast activation protein α (FAP‑α) protein expression. It was revealed that TMZ resistance promoted the formation of CICs and upregulated FAP‑α expression in glioblastoma cells. Over‑expressing FAP‑α was also demonstrated to promote TMZ resistance and induce the formation of CICs in U251MG cells. In addition, using a reverse transcription‑quantitative polymerase chain reaction, it was observed that miR‑204 was downregulated in U251MG‑resistant (‑R) cells. miR‑204 expression negatively correlated with the FAP‑α levels in human glioblastoma tissues, and it may inhibit the formation of CICs and reverse TMZ resistance in U251MG‑R cells. Therefore, it was concluded that miR‑204 reversed temozolomide resistance and inhibited CICs phenotypes by degrading FAP-α in glioblastoma.
View Figures
View References

Related Articles

Journal Cover

May-2018
Volume 15 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yang YN, Zhang XH, Wang YM, Zhang X and Gu Z: miR-204 reverses temozolomide resistance and inhibits cancer initiating cells phenotypes by degrading FAP-α in glioblastoma. Oncol Lett 15: 7563-7570, 2018
APA
Yang, Y., Zhang, X., Wang, Y., Zhang, X., & Gu, Z. (2018). miR-204 reverses temozolomide resistance and inhibits cancer initiating cells phenotypes by degrading FAP-α in glioblastoma. Oncology Letters, 15, 7563-7570. https://doi.org/10.3892/ol.2018.8301
MLA
Yang, Y., Zhang, X., Wang, Y., Zhang, X., Gu, Z."miR-204 reverses temozolomide resistance and inhibits cancer initiating cells phenotypes by degrading FAP-α in glioblastoma". Oncology Letters 15.5 (2018): 7563-7570.
Chicago
Yang, Y., Zhang, X., Wang, Y., Zhang, X., Gu, Z."miR-204 reverses temozolomide resistance and inhibits cancer initiating cells phenotypes by degrading FAP-α in glioblastoma". Oncology Letters 15, no. 5 (2018): 7563-7570. https://doi.org/10.3892/ol.2018.8301